AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...
Seoul National University Bundang Hospital ('SNUBH'), CurePSP, Inc. ('CurePSP') and GemVax & KAEL Co., Ltd. ('GemVax'; KOSDAQ: 082270) have announced the establishment of Korea's first International P ...
Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...
J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA ...
AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.
"The best medication for Parkinson's will come from Israel. It will be a hybrid medication, and the world's best hybrid ...
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.
Stephen Knight, whose nonprofit saves lives by providing foster care for dogs while their owners focus on addiction recovery, ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...